Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 2
1963 3
1964 1
1965 2
1971 1
1972 4
1973 14
1974 9
1975 16
1976 12
1977 17
1978 24
1979 14
1980 19
1981 22
1982 23
1983 15
1984 17
1985 16
1986 17
1987 16
1988 10
1989 21
1990 17
1991 20
1992 21
1993 18
1994 20
1995 17
1996 8
1997 19
1998 20
1999 19
2000 20
2001 24
2002 15
2003 13
2004 18
2005 15
2006 28
2007 36
2008 29
2009 30
2010 32
2011 40
2012 51
2013 40
2014 48
2015 43
2016 49
2017 46
2018 58
2019 58
2020 63
2021 68
2022 64
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

1,285 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Corso CR, Acco A, Bach C, Bonatto SJR, de Figueiredo BC, de Souza LM. Corso CR, et al. Br J Clin Pharmacol. 2021 Jul;87(7):2698-2710. doi: 10.1111/bcp.14721. Epub 2021 Feb 2. Br J Clin Pharmacol. 2021. PMID: 33382119 Free article. Review.
Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC). ...Therefore, the aim of this review was to summarize the chemistry, pharmacokinetics and pharmacodynamics, and therapeutic and toxic effects of
Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC). ...Th
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
Haider MS, Ahmad T, Groll J, Scherf-Clavel O, Kroiss M, Luxenhofer R. Haider MS, et al. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34287806 Free PMC article. Review.
Moreover, we present recent efforts to improve mitotane formulations. Their success has been limited, and we therefore propose an injectable mitotane formulation instead of oral administration, which could bypass many of the main issues associated with high-dose ora …
Moreover, we present recent efforts to improve mitotane formulations. Their success has been limited, and we therefore propose an inj …
Understanding mitotane mode of action.
Waszut U, Szyszka P, Dworakowska D. Waszut U, et al. J Physiol Pharmacol. 2017 Feb;68(1):13-26. J Physiol Pharmacol. 2017. PMID: 28456766 Free article. Review.
Adrenocortical carcinoma is a rare disease with poor prognosis. Mitotane is the most effective agent in post-operative treatment (or when inoperable). ...We consider features of the adrenal cortex that might explain mitotane selectivity, and review effects on non-ad …
Adrenocortical carcinoma is a rare disease with poor prognosis. Mitotane is the most effective agent in post-operative treatment (or …
Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
Warde KM, Lim YJ, Ribes Martinez E, Beuschlein F, O'Shea P, Hantel C, Dennedy MC. Warde KM, et al. Endocrinology. 2022 Sep 1;163(9):bqac102. doi: 10.1210/endocr/bqac102. Endocrinology. 2022. PMID: 35797592 Free PMC article.
METHODOLOGY: ATCC-H295R (mitotane-sensitive) and MUC-1 (mitotane-resistant) ACC cells were evaluated for lipid content using specific BODIPY dyes. ...Decreased lipid droplets were associated with increased lipolysis in H295R and in MUC-1 at toxic mitotane con …
METHODOLOGY: ATCC-H295R (mitotane-sensitive) and MUC-1 (mitotane-resistant) ACC cells were evaluated for lipid content using s …
Mitotane for adrenocortical carcinoma treatment.
Hahner S, Fassnacht M. Hahner S, et al. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. Curr Opin Investig Drugs. 2005. PMID: 15898346 Review.
It is known that metabolic activation is essential for the adrenolytic activity of mitotane. Most published clinical reports of mitotane use are retrospective analyses of small numbers of patients, however, the collective findings of these studies indicate that m
It is known that metabolic activation is essential for the adrenolytic activity of mitotane. Most published clinical reports of mi
Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy.
Altieri B, Lalli E, Faggiano A. Altieri B, et al. Minerva Endocrinol (Torino). 2022 Jun;47(2):203-214. doi: 10.23736/S2724-6507.21.03601-0. Epub 2021 Dec 9. Minerva Endocrinol (Torino). 2022. PMID: 34881855
However, evidence on mitotane efficacy is mostly based on retrospective studies and the use of mitotane continues to represent a clinical challenge. ...Different clinical and molecular markers predicting response to mitotane have been proposed with uncertain …
However, evidence on mitotane efficacy is mostly based on retrospective studies and the use of mitotane continues to represent …
Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M, Zaggia B, Allasino B, De Francia S. Terzolo M, et al. Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):159-65. doi: 10.1097/MED.0000000000000056. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 24732405 Free article. Review.
The concept of a therapeutic window of mitotane plasma concentrations was confirmed also for adjunctive treatment, but the relationship between mitotane concentration and given dose is loose. ...In advanced adrenocortical carcinoma, a high-dose starting regimen shou …
The concept of a therapeutic window of mitotane plasma concentrations was confirmed also for adjunctive treatment, but the relationsh …
How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives.
Steenaard RV, Ettaieb MHT, Kerkhofs TMA, Haak HR. Steenaard RV, et al. Expert Opin Drug Metab Toxicol. 2021 Jun;17(6):677-683. doi: 10.1080/17425255.2021.1921146. Epub 2021 May 4. Expert Opin Drug Metab Toxicol. 2021. PMID: 33886381 Review.
INTRODUCTION: Mitotane is the only drug registered specifically for adrenocortical carcinoma. Finding the optimal dose for a patient is difficult due to large differences in bioavailability, toxicity and effect. We therefore look to improve personalized dosing of mitota
INTRODUCTION: Mitotane is the only drug registered specifically for adrenocortical carcinoma. Finding the optimal dose for a patient …
Key factors for effective mitotane therapy in children with adrenocortical carcinoma.
Kuhlen M, Mier P, Kunstreich M, Lessel L, Schneider D, Brecht I, Schewe DM, Frühwald MC, Vorwerk P, Redlich A. Kuhlen M, et al. Endocr Relat Cancer. 2022 Aug 1;29(9):545-555. doi: 10.1530/ERC-22-0146. Print 2022 Sep 1. Endocr Relat Cancer. 2022. PMID: 35900840
Cox regression determined the risk of event decreasing by 10.4% for each month of mitotane treatment (P = 0.015). Re-treatment with mitotane after first-line treatment proved ineffective. The duration of mitotane treatment and reaching mitotane TR sign …
Cox regression determined the risk of event decreasing by 10.4% for each month of mitotane treatment (P = 0.015). Re-treatment with …
Mitotane (o,p'-DDD).
Gutierrez ML, Crooke ST. Gutierrez ML, et al. Cancer Treat Rev. 1980 Mar;7(1):49-55. doi: 10.1016/s0305-7372(80)80025-9. Cancer Treat Rev. 1980. PMID: 7397707 No abstract available.
1,285 results